Mike Musgnug

Independent Director

Mr. Musgnug serves as Chief Commercial Officer at Standard BioTools (NASDAQ: LAB), a provider of genomics and proteomics research tools. Prior to that he was CEO of GrapheneDx, a point-of-care and consumer diagnostics company. He has built a decadeslong career in Diagnostics and Life Sciences with various executive roles at Alere (subsequently acquired by Abbott), Cepheid (acquired by Danaher) and Beckman Coulter Life Sciences (a Danaher operating company). Mr. Musgnug held roles in commercial leadership, strategy, and general management with a focus on scaling disruptive diagnostics technologies. Mr. Musgnug holds a MS from University of Massachusetts Lowell, an MBA from Marist University and a BS from Marist University.

Bradley Meyer

Chairman of the Board

Mr. Meyer has 25+ years of experience in investment banking and strategic advisory and has worked on a broad range of assignments across a number of industry sectors.

Jeri Hilleman

Independent Director

Ms. Hilleman is Chairperson of the Board of Omada Health, and currently serves on boards including NovoCure (NASDAQ: NVCR) and SI-Bone (NASDAQ: SIBN).

Roger Moody

Chief Executive Officer

Mr. Moody has more than 30 years of experience in the life science and medical technology market, experienced in scaling up public and private companies.

Mike Musgnug

Independent Director

Dr. David H. Persing, MD, PhD

Independent Director

Dr. Persing was Executive Vice President and Chief Medical & Scientific Officer at Cepheid, and was the Chief Scientific Officer for the Danaher Diagnostics platform after the acquisition of Cepheid in 2016.